Lixte Biotechnology Files 8-K
Ticker: LIXT · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $2.6 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, biotechnology
Related Tickers: LIXT
TL;DR
LIXT filed an 8-K on 9/11 for an event on 9/10. Check for details.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an 8-K on September 11, 2025, reporting an event that occurred on September 10, 2025. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is incorporated in Delaware and its principal executive offices are located in Pasadena, California.
Why It Matters
This 8-K filing indicates a material event has occurred for Lixte Biotechnology Holdings, Inc., requiring public disclosure. Investors should review the filing for details on the nature of the event.
Risk Assessment
Risk Level: low — This filing is a standard 8-K disclosure and does not inherently present new risks without further context from the filing's content.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- September 11, 2025 (date) — Date of Report
- September 10, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- Pasadena, California (location) — Principal Executive Offices
FAQ
What specific event triggered this 8-K filing?
The filing does not specify the exact event, only that it occurred on September 10, 2025, and is being reported on September 11, 2025, under Regulation FD Disclosure and Financial Statements and Exhibits.
What is the company's primary business?
Lixte Biotechnology Holdings, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
When is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the company's SEC file number?
The SEC file number for Lixte Biotechnology Holdings, Inc. is 001-39717.
Where are Lixte Biotechnology's principal executive offices located?
The principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101.
Filing Stats: 777 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2025-09-11 13:28:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
- $2.6 million — y issued a press release announcing the $2.6 million initial purchase of digital currency, a
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001641172-25-027109.txt ( ) — 266KB
- lixt-20250911.xsd (EX-101.SCH) — 4KB
- lixt-20250911_def.xml (EX-101.DEF) — 26KB
- lixt-20250911_lab.xml (EX-101.LAB) — 36KB
- lixt-20250911_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 11, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ Geordan Pursglove Geordan Pursglove Chairman of the Board and Chief Executive Officer